` ABEO (Abeona Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

ABEO
vs
S&P 500

Over the past 12 months, ABEO has significantly outperformed S&P 500, delivering a return of 65% compared to the S&P 500's 8% growth.

Stocks Performance
ABEO vs S&P 500

Loading
ABEO
S&P 500
Add Stock

Performance Gap
ABEO vs S&P 500

Loading
ABEO
S&P 500
Difference

Performance By Year
ABEO vs S&P 500

Loading
ABEO
S&P 500
Add Stock

Competitors Performance
Abeona Therapeutics Inc vs Peers

S&P 500
ABEO
ABBV
AMGN
GILD
VRTX
Add Stock

Abeona Therapeutics Inc
Glance View

Market Cap
246m USD
Industry
Biotechnology

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in New York City, New York and currently employs 90 full-time employees. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.

ABEO Intrinsic Value
12.2 USD
Undervaluation 56%
Intrinsic Value
Price
Back to Top